Merck KGaA (MRK) Given Average Rating of “Hold” by Analysts

Merck KGaA (FRA:MRK) has earned a consensus rating of “Hold” from the twenty-two analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is €99.15 ($115.29).

MRK has been the topic of a number of analyst reports. Warburg Research set a €100.00 ($116.28) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Tuesday, August 28th. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 9th. JPMorgan Chase & Co. set a €90.00 ($104.65) target price on Merck KGaA and gave the company a “neutral” rating in a research note on Monday, June 4th. Barclays set a €70.00 ($81.40) target price on Merck KGaA and gave the company a “sell” rating in a research note on Friday, August 24th. Finally, UBS Group set a €115.00 ($133.72) target price on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 9th.

Shares of FRA MRK opened at €88.10 ($102.44) on Thursday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply